The online version of this article (doi:10.1186/1475-2875-11-433) contains supplementary material, which is available to authorized users.
The investigations were financially supported by Pfizer Pharmaceutical Laboratories, West Africa, who also supplied the anti-malarials drugs used for this study.
BF wrote the paper; BF, JLN, RCT, KS supervised field work and data collection in Senegal, analysed data of Senegal and analysed from the three countries, reviewed and approved the manuscript; TK, TN collected and analysed data in Cameroon, reviewed and approved the manuscript; EIHM, CPK, CA A collected and analysed data in Ivory Coast, reviewed and approved the manuscript; OG coordinated the study in the three countries, reviewed and approved the manuscript; OF coordinated the study in Senegal, reviewed and approved the manuscript; AS coordinated the study in Cameroon (data collection and analysis) reviewed and approved the manuscript; MK coordinated (data collection and analysis) the study in Ivory Coast, reviewed and approved the manuscript. All authors read and approved the final manuscript.
This multicentre study was carried out in Cameroon, Ivory Coast and Senegal to evaluate the non-inferiority of the new paediatric formulation of artesunate/amodiaquine (AS+AQ)(Camoquin-Plus Paediatric®) in suspension form versus artemether/lumefantrine (AL)(Coartem®) in the management of African children with uncomplicated falciparum malaria.
It was an open randomized trial including children aged between 7 months and 7 years. The endpoints were Adequate Clinical and Parasitological Response (ACPR) at day 28, the clinical and biological tolerability. Statistical analyses were done in Intention To Treat (ITT) and in Per protocol (PP).
At the end of the study 481 patients were enrolled in the three countries (249 in the AS+AQ arm and 232 in the AL arm). ACRP in ITT after PCR correction did not show any statistical difference between the two groups with 97.6% for AS+AQ versus 94.8% for AL. In the PP analysis, the corrected ACRP were respectively 98.7% and 96.9% for the two regimens. The clinical tolerance was good without significant difference. Anaemia was significantly higher at D7 in the two groups compared to D0.
This study demonstrates the non-inferiority of AS+AQ versus AL, its efficacy and tolerance in the management of uncomplicated Plasmodium falciparum malaria in African children.
World Health Organization: World Malaria Report. 2005, Geneva: WHO/HTM/MAL/2005.1102
World Health Organization: Les combinaisons thérapeutiques antipaludiques: Rapport d'une consultation technique de l'OMS. 2001, Geneva: WHO/CDS/RBM/2001.35
Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, Cohuet S, D'Alessandro U, Djimdé A, Karema C, Guthmann JP, Hamour S, Ndiaye JL, Mårtensson A, Rwagacondo C, Sagara I, Same-Ekobo A, Sirima SB, Van den Broek I, Yeka A, Taylor WR, Dorsey G, Randrianarivelojosia M: Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009, 8: 203-10.1186/1475-2875-8-203. PubMedCentralCrossRefPubMed
World Health Organization: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. 2003, Geneva: WHO/HTM/RBM/2003.50
World Health Organization: Severe falciparum malaria. 2003, Geneva: WHO/HTM/RBM/2003.50
Faye B, Ndiaye JL, Tine RC, Sylla K, Gueye A, Lo A, Gaye O: A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am J Trop Med Hyg. 2010, 82: 140-144. 10.4269/ajtmh.2010.09-0265. PubMedCentralCrossRefPubMed
Kafatos G, Verlander NQ, Gelb D, Arnold E, Charlett A: A comparison of public domain software for outbreak investigations: Epi Info and EpiData. Eurosurveillance. 2007, 12: 11-
Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LCKitcher ED, Badoe EV, Lamptey R, Goka BQ: Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J. 2008, 7: 127-10.1186/1475-2875-7-127. PubMedCentralCrossRefPubMed
Thanh NX, Trung TN, Phong NC, Thien NX, Dai B, Shanks GD, Chavchich M, Edstein MD: Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop Med Int Health. 2009, 14: 504-511. 10.1111/j.1365-3156.2009.02269.x. CrossRefPubMed
Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK, Gyapong J, Greenwood B, Chandramohan D: An open label, randomised trial of artesunate plus amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. PLoS One. 2008, 3: e2530-10.1371/journal.pone.0002530. PubMedCentralCrossRefPubMed
Tall A, Rabarijaona LP, Robert V, Bedja SA, Ariey F, Randrianarivelojosia M: Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union. Acta Trop. 2007, 102: 76-81. CrossRef
Swarthout TD, Van den Broek IV, Kayembe G, Montgomery J, Pota H, Roper C: Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. Trop Med Int Health. 2006, 11: 1503-1511. 10.1111/j.1365-3156.2006.01710.x. CrossRefPubMed
Ibrahium AM, Kheir MM, Osman ME, Khalil IF, Alifrangis M, Elmardi KA, Malik EM, Adam I: Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol. 2007, 101: 15-21. 10.1179/136485907X156924. CrossRefPubMed
Ndiaye JL, Faye B, Diouf AM, Kuété T, Cisse M, Seck PA, Brasseur P, Same-Ekobo A, Lameyre V, Gaye O: Randomized, comparative study of the efficacy and safety of artesunate plus amodiaquine, administered as a single daily intake versus two daily intakes in the treatment of uncomplicated falciparum malaria. Malar J. 2008, 7: 16-10.1186/1475-2875-7-16. PubMedCentralCrossRefPubMed
Taylor WR, Terlouw DJ, Olliaro PL, White NJ, Brasseur P, Kuile FO: Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull World Health Organ. 2006, 84: 956-964. 10.2471/BLT.06.031492. PubMedCentralCrossRefPubMed
Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, Houzé P, Kossou H, Amedome H, Massougbodji A, Cot M, Deloron P: Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness non inferiority trial. J Infect Dis. 2009, 200: 57-65. 10.1086/599378. CrossRefPubMed
Oduro AR, Anyorigiya T, Anto F, Amenga-Etego L, Ansah NA, Atobrah P, Ansah P, Koram K, Hodgson A: A randomized, comparative study of supervised and unsupervised artesunate-amodiaquine, for the treatment of uncomplicated malaria in Ghana. Ann Trop Med Parasitol. 2008, 102: 565-576. 10.1179/136485908X337508. CrossRefPubMed
Sowunmi A, Balogun T, Gbotosho GO, Happi CT, Adedeji AA, Fehintola FA: Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in children. Antimicrob Agents Chemother. 2007, 51: 1694-1699. 10.1128/AAC.00077-07. PubMedCentralCrossRefPubMed
- Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal
Christiane P Kiki-Barro
Roger C Tine
Jean Louis A Ndiaye
Claude A Kakpo
Hervé EI Menan
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II